Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration ...

“So we continued her on Eylea injection here, her OCT scan passing through the fovea which is pretty much maintained at 20/30, and we continued her on Eylea, and here you can see that she has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

May 23, 2025 Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

“So what were the treatment options available? At that point, we had only three drugs available, Avastin, Lucentis, and Eylea. However, you can see the bottom part where we have a long list of ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a ...